As of May 23, 2025, Sutro Biopharma Inc (STRO) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Sutro Biopharma Inc's Forward P/E to Peers
To better understand Sutro Biopharma Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Sutro Biopharma Inc (STRO) | - |
| MeiraGTx Holdings PLC (MGTX) | 204.69 |
| Theratechnologies Inc (TH.TO) | 77.29 |
| Vertex Pharmaceuticals Inc (VRTX) | 23.76 |
| MannKind Corp (MNKD) | 22.98 |
| Regeneron Pharmaceuticals Inc (REGN) | 16.41 |
Compared to its competitors, Sutro Biopharma Inc's Forward P/E is difficult to compare due to insufficient data.